PTC Therapeutics (PTCT) announced that the FDA accelerated approval of its gene therapy for the treatment of AADC deficiency, the first-ever ...

Key events this week, including the US CPI data and the speech by the Federal Reserve Chair, will be critical in providing ...

In a report released today, Jason Celino from KeyBanc maintained a Buy rating on PTC (PTC – Research Report). The company’s shares ...

PTC projected adjusted earnings per share of 75 cents to 95 cents for the quarter, compared with analysts' estimate of $1.33. For the fiscal year 2025, PTC expects revenue to be between $2.51 billion ...

A trader wears a hat in support of Republican Donald Trump, after he won the U.S. presidential election, at the New York ...

Panellists were announced during annual conference for The Personal Travel Consultants in Partnership with Blue Bay Travel, ...

Berenberg downgraded PTC ( PTC, Financials) to hold from buy on Friday, citing a lack of stabilization in key markets that have continued to experience macroeconomic challenges, particularly aerospace ...

ICON plc (NASDAQ:ICLR) traded sharply lower on Thursday, sparking a selloff among its rival contract research organizations after the Ireland-based company cut its guidance with its Q3 results. In ...

“A multitalented personality, the actress, producer and fashion icon henceforth embodies the audacity, grace and elegance of Dior style, a femininity constantly reinvented,” the press release ...

Potential bidders include rival design software makers such as PTC and Cadence Design Systems, the sources said. Reuters could not determine whether PTC and Cadence have approached Altair.

The therapy’s maker, PTC Therapeutics, is committed to keeping Translarna available in the meantime. “As Translarna will remain authorized in Europe pending review by the European Commission, we will ...